40 related articles for article (PubMed ID: 19661031)
1. Non-canonical WNT6/WNT10A signal factor expression in EBV+ post-transplant smooth muscle tumors.
Teiken K; Kuehnel M; Rehkaemper J; Kreipe H; Laenger F; Hussein K; Jonigk D
Clin Sarcoma Res; 2018; 8():10. PubMed ID: 29881541
[TBL] [Abstract][Full Text] [Related]
2. Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy.
Ali Y; Abd Hamid S
Tumour Biol; 2016 Jan; 37(1):47-55. PubMed ID: 26482620
[TBL] [Abstract][Full Text] [Related]
3. Down-regulated E-cadherin expression is associated with poor five-year overall survival in bone and soft tissue sarcoma: results of a meta-analysis.
Wang N; He YL; Pang LJ; Zou H; Liu CX; Zhao J; Hu JM; Zhang WJ; Qi Y; Li F
PLoS One; 2015; 10(3):e0121448. PubMed ID: 25822802
[TBL] [Abstract][Full Text] [Related]
4. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.
Lusby K; Savannah KB; Demicco EG; Zhang Y; Ghadimi MP; Young ED; Colombo C; Lam R; Dogan TE; Hornick JL; Lazar AJ; Hunt KK; Anderson ML; Creighton CJ; Lev D; Pollock RE
Ann Surg Oncol; 2013 Jul; 20(7):2364-72. PubMed ID: 23334251
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of E-cadherin and Vimentin expression in various subtypes of soft tissue leiomyosarcomas.
Tian W; Wang G; Yang J; Pan Y; Ma Y
Med Oncol; 2013 Mar; 30(1):401. PubMed ID: 23292832
[TBL] [Abstract][Full Text] [Related]
6. Expression of E-cadherin, beta-catenin and topoisomerase IIalpha in leiomyosarcomas.
Gogou PN; Batistatou A; Pakos EE; Apostolikas N; Stefanou D; Tsekeris PG
Clin Transl Oncol; 2009 Aug; 11(8):548-51. PubMed ID: 19661031
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic study of E-cadherin/beta-catenin complex, and topoisomerase-II in a series of 71 liposarcoma cases.
Gogou P; Pakos E; Batistatou A; Panelos I; Briasoulis E; Stefanou D; Apostolikas N; Tsekeris P
World J Surg Oncol; 2012 Feb; 10():28. PubMed ID: 22300273
[TBL] [Abstract][Full Text] [Related]
8. Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin.
Gaumann A; Tews DS; Mentzel T; Petrow PK; Mayer E; Otto M; Kirkpatrick CJ; Kriegsmann J
Virchows Arch; 2003 Jun; 442(6):529-37. PubMed ID: 12743815
[TBL] [Abstract][Full Text] [Related]
9. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
[TBL] [Abstract][Full Text] [Related]
10. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex.
Huang L; Shitashige M; Satow R; Honda K; Ono M; Yun J; Tomida A; Tsuruo T; Hirohashi S; Yamada T
Gastroenterology; 2007 Nov; 133(5):1569-78. PubMed ID: 17983804
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin, b-catenin and topoisomerase II expression in rhabdomyosarcomas.
Gogou PN; Batistatou A; Pakos EE; Apostolikas N; Stefanou D; Tsekeris PG
J BUON; 2009; 14(2):323-4. PubMed ID: 19650189
[No Abstract] [Full Text] [Related]
12. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation.
Muller S; Su L; Tighiouart M; Saba N; Zhang H; Shin DM; Chen Z
Cancer; 2008 Jul; 113(1):97-107. PubMed ID: 18473353
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]